ARTLARTELO BIOSCIENCES, INC.

Nasdaq artelobio.com


$ 1.19 $ 0.06 (4.99 %)    

Monday, 09-Sep-2024 15:50:31 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 1.26
$ 1.19 x 100
-- x --
-- - --
$ 1.15 - $ 1.78
6,986
na
4.07M
$ 1.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-25-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 01-12-2022 11-30-2021 10-Q
12 11-29-2021 08-31-2021 10-K
13 07-12-2021 05-31-2021 10-Q
14 04-13-2021 02-28-2021 10-Q
15 01-14-2021 11-30-2020 10-Q
16 11-04-2020 08-31-2020 10-K
17 07-13-2020 05-31-2020 10-Q
18 04-13-2020 02-29-2020 10-Q
19 01-14-2020 11-30-2019 10-Q
20 11-25-2019 08-31-2019 10-K
21 07-15-2019 05-31-2019 10-Q
22 04-15-2019 02-28-2019 10-Q
23 01-14-2019 11-30-2018 10-Q
24 11-29-2018 08-31-2018 10-K
25 07-13-2018 05-31-2018 10-Q
26 04-16-2018 02-28-2018 10-Q
27 01-16-2018 11-30-2017 10-Q
28 11-29-2017 08-31-2017 10-K
29 07-21-2017 05-31-2017 10-Q
30 04-14-2017 02-28-2017 10-Q
31 01-10-2017 11-30-2016 10-Q
32 11-29-2016 08-31-2016 10-K
33 07-05-2016 05-31-2016 10-Q
34 04-01-2016 02-29-2016 10-Q
35 01-14-2016 11-30-2015 10-Q
36 12-11-2015 08-31-2015 10-K
37 07-15-2015 05-31-2015 10-Q
38 04-14-2015 02-28-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-artelo-biosciences-maintains-5-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Artelo Biosciences (NASDAQ:ARTL) with a Buy and maintains $5 pr...

 artelo-biosciences-q2-eps-075-beats-085-estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(...

Core News & Articles
Market-Moving News for July 15th
07/15/2024 12:38:19

DJT: 75% | Trump Media & Technology Group shares are trading higher following the attempted assassination of Donald Trump. ...

 hc-wainwright--co-reiterates-buy-on-artelo-biosciences-maintains-5-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Artelo Biosciences (NASDAQ:ARTL) with a Buy and maintains $5 pr...

 hc-wainwright--co-reiterates-buy-on-artelo-biosciences-maintains-5-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Artelo Biosciences (NASDAQ:ARTL) with a Buy and maintains $5 pr...

 artelo-biosciences-q1-eps-078-beats-105-estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(...

 hc-wainwright--co-maintains-buy-on-artelo-biosciences-maintains-5-price-target

HC Wainwright & Co. analyst Vernon Bernardino maintains Artelo Biosciences (NASDAQ:ARTL) with a Buy and maintains $5 pri...

 artelo-biosciences-earlier-reported-q4-eps-099-misses-056-estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of ...

 artelo-biosciences-fy23-eps-314-vs-356-yoy

Fiscal 2023 Year-End Financial ResultsCash and Investments: Cash and investments totalled $10.4 million as of December 31, 2023...

 artelo-biosciences-has-been-granted-european-patent-number-ep3723752-titled-new-solid-forms-of-cannabidiol-and-uses-thereof-for-various-medical-treatments

https://register.epo.org/application?number=EP18887462 

 artelo-biosciences-announces-publication-of-new-peer-reviewed-pre-clinical-research-demonstrating-art2612s-effectiveness-in-treating-and-preventing-oxaliplatin-induced-peripheral-neuropathy

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways...

 artelo-biosciences-announces-selection-of-worldwide-clinical-trials-as-clinical-research-organization-to-support-first-in-human-study-of-art2612

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION